Premium
P2–241: Plasma testosterone levels and cognitive function in borderline hypogonadal older men
Author(s) -
Heyn Patricia C.,
Schwartz Robert S.,
Nakamura Tammie
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1080
Subject(s) - testosterone (patch) , cohort , cognition , medicine , cognitive test , psychology , gerontology , cognitive impairment , psychiatry
disease (cerebral, cardiac or peripheral arterial disease). These VRF were considered present according to history, medication used, examination or laboratory results at the first standardised evaluation. They were considered treated if they received, respectively, an antihypertensive, an oral antihyperglycemic or insulin, a statin or a fibrate, an antiplatelet or an anticoagulant. Preliminary Results: Among the first 406 patients included (approximately 57% of the whole cohort), 377 (92.1%) had at least one VRF. Only 121 (32.1%) had all their VRF treated (treated group). We compared them with the 83 (22%) who had none of their VRF treated (untreated group). Both groups were similar for age (73.1 years), sex distribution (62.6% women), educational level (76.5% lower level), baseline MMSE (21.7), final diagnosis (60.1% AD), acetyl-cholinesterase inhibitors utilization (67%), and follow-up length (3.5 years). MMSE evolution over time was compared between treated and untreated groups with a mixed model adjusted for age, sex, education, first MMSE, diagnosis and year of first visit. Overall, MMSE decline is significantly slower in the treated group (p 0.003, figure 1). For pure AD cases (n 128), a similar trend emerges but does not reach statistical significance (p 0.073, figure 2).